Abstract:Background: Cannabinoids bind to cannabinoid receptors type 1 and 2 and produce analgesia in several pain models, but central side effects from cannabinoid 1 receptors limit their clinical use. Because of the pain-relieving effects of cannabinoid 2 (CB2) receptor agonists in inflammation pain, incision pain, and neuropathic pain models, we tested whether spinal CB2 receptor activation would induce antihyperalgesia in cancer pain. Our previous study showed that the 2B subunit of N-methyl-D-aspartate (NR2B) receptor in the spinal cord participates in bone cancer pain in mice. In the present study, we also tested the cannabinoid effect on the expression of NR2B. Methods: Seventy-two mice were randomly allocated to 7 different groups: (1) control; (2) sham and tumor-bearing mice, which include (3) V; (4) J1; (5) J2; (6) J3; and (7) J4. In the groups of tumor-bearing mice, C(3)H/Hej mice were implanted with NCTC2472 fibrosarcoma cells into the femur bone to induce bone cancer-related pain behaviors. The sham mice were implanted with minimal essential medium α modification, whereas the control mice received no injection. On day 14 after implantation, tumor-invoked tactile allodynia and thermal hyperalgesia were assessed. Tumor-bearing mice were assigned to intrathecal administration of the CB2 receptor agonist JWH015 (0.5, 1, and 2 μg), CB2 receptor antagonist AM630 (2 μg), or vehicle, and the assessment of withdrawal thresholds was then performed. Tactile allodynia and thermal hyperalgesia were assessed before administration and at 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours after administration. Spinal NR2B activation of all tumor-bearing mice at 12 hours and 72 hours were determined by reverse transcription-polymerase chain reaction analyses. Results: At day 14 after operation, tumor-evoked tactile allodynia and thermal hyperalgesia were higher in tumor-bearing mice compared with the sham and control mice. Intrathecal administration of JWH015 dose dependently attenuated tumor-evoked tactile allodynia and thermal hyperalgesia but this effect was prevented by intrathecal administration of AM630 30 minutes before. The mRNA expression of NR2B was similar to this result. At 12 hours after administration, the expression of NR2B mRNA in the spinal cord was lower in mice that were administered JWH015 compared with the vehicle group. However, this phenomenon was reversed in the group that was preadministered AM630. Conclusion: These data indicated that intrathecal administration of cannabinoid receptor agonists might relieve cancer pain, probably by reducing NR2B-dependent activity in the spinal cord. These results also suggested that cannabinoids might be a useful alternative or adjunct therapy for relieving cancer pain.

Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests

Evaluation of the terpenes β-caryophyllene, α-terpineol, and γ-terpinene in the mouse chronic constriction injury model of neuropathic pain: possible cannabinoid receptor involvement

Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.

Evaluating the Antinociceptive Efficacy of Cannabidiol Alone or in Combination with Morphine Using the Formalin Test in Male and Female Mice.

The Analgesic Effects of (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] Octane on a Mouse Model of Neuropathic Pain.

Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination

Single and Combined Effects of Cannabigerol (CBG) and Cannabidiol (CBD) in Mouse Models of Oxaliplatin-Associated Mechanical Sensitivity, Opioid Antinociception, and Naloxone-Precipitated Opioid Withdrawal

Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model

The Analgesia Effect of Aucubin on CFA-Induced Inflammatory Pain by Inhibiting Glial Cells Activation-Mediated Inflammatory Response via Activating Mitophagy

Cannabigerol (CBG) Attenuates Mechanical Hypersensitivity Elicited by Chemotherapy‐induced Peripheral Neuropathy

Synthesis And Antiallodynic Activity Of Cannabidiol Analogue On Peripheral Neuropathy In Mice

Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS‐13019 in mouse models of pain and reinforcement

Cannabis sativa L. Extract Alleviates Neuropathic Pain and Modulates CB1 and CB2 Receptor Expression in Rat

Analgesic Effects of NB001 on Mouse Models of Arthralgia.

Transcriptomic Profiling in Mice With CB1 receptor Deletion in Primary Sensory Neurons Suggests New Analgesic Targets for Neuropathic Pain

Contribution Of Opioid Receptors To Antinociception Produced By ß‐Caryophyllene

Analgesic Tolerance and Cross-Tolerance to the Cannabinoid Receptors Ligands Hemopressin, VD-hemopressin(α) and WIN55,212-2 at the Supraspinal Level in Mice

Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation

Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D-aspartic acid

Potential analgesic effect of a novel cannabidiol nanocrystals powder for the treatment of neuropathic pain

In Vitro and In Vivo Anti-Inflammatory Potential of Cannabichromene Isolated from Hemp